Last quarter (Q ), Q BioMed's total revenue was $―, a decrease of -100.00% from the same quarter last year. In Q, Q BioMed's net income was $-721.61K. See Q BioMed’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Nov 22	Nov 21	Nov 20	Nov 19	Nov 18
Total Revenue	$ 209.29K	$ 284.35K	$ 195.60K	$ 30.00K	$ 0.00	$ 0.00
Cost of Revenue	$ 515.29K	$ 293.34K	$ 246.85K	$ 326.01K	$ 0.00	-
Gross Profit	$ -12.60K	$ -8.99K	$ -51.25K	$ -296.01K	$ 0.00	-
Operating Expense	$ 7.11M	$ 3.44M	$ 7.34M	$ 12.85M	$ 8.02M	$ 9.02M
Operating Income	$ -2.45M	$ -3.17M	$ -7.39M	$ -13.15M	$ -8.02M	$ -9.02M
Net Non Operating Interest Income Expense	$ -1.25M	$ -1.38M	$ -506.92K	$ -296.21K	$ -1.46M	$ -162.10K
Other Income Expense	$ -2.71M	$ -2.50M	$ 40.91K	$ -50.56K	$ -799.39K	$ -89.00K
Pretax Income	$ -1.95M	$ -2.05M	$ -7.94M	$ -13.49M	$ -10.28M	$ -9.27M
Tax Provision	-	-	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -1.84M	$ -3.49M	$ -8.44M	$ -14.35M	$ -10.28M	$ -9.27M
Basic EPS	$ -0.02	$ -0.08	$ -0.33	$ -0.65	$ -0.68	$ -0.67
Diluted EPS	$ -0.02	$ -0.08	$ -0.33	$ -0.65	$ -0.68	$ -0.67
Basic Average Shares	$ 231.39M	$ 44.76M	$ 26.78M	$ 22.16M	$ 15.04M	$ 13.74M
Diluted Average Shares	$ 231.39M	$ 44.76M	$ 26.78M	$ 22.16M	$ 15.04M	$ 13.74M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 7.62M	$ 3.73M	$ 7.58M	$ 13.18M	$ 8.02M	$ 9.02M
Net Income From Continuing And Discontinued Operation	$ -517.18K	$ -2.05M	$ -7.94M	$ -13.49M	$ -10.28M	$ -9.27M
Normalized Income	$ -1.39M	-	-	$ -13.44M	$ -10.07M	$ -9.18M
Interest Expense	$ 454.00K	-	-	$ 296.21K	$ 1.46M	$ 162.10K
EBIT	$ -253.90K	$ -667.63K	$ -7.43M	$ -13.20M	$ -8.82M	$ -9.11M
EBITDA	$ -216.40K	$ -617.63K	$ -7.38M	$ -13.15M	$ -8.77M	$ -9.11M

Currency in USD

Q BioMed Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing